Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 7/20 | 0.44 |
| ▸ | NPY1R | P25929 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29027297 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL940540 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL14840576 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL2762373 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL940539 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL42488 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL2172217 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL157856 | 0.98 | NPY4R (0.45) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| Guanidine SCHEMBL8907224 | 0.97 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R | |
| SCHEMBL2236129 | 0.97 | NPY4R (0.44) | NPY4RNPY1RDPP7NPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-106178988-B | A kind of polyvinylidene fluoride blending film of photosynthesis-carbon dioxide response and preparation method thereof | 台州学院 | 2019-09-24 | — | — | CN | claimed |
| US-20120076859-A1 | Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases | ACTIVAERO GMBH (DE) | 2012-03-29 | — | — | US | claimed |
| EP-1865978-A2 | NEW NEURONAL PAIN PATHWAY | The Trustees of Columbia University in the City of New York (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006102267-A2 | NEW NEURONAL PAIN PATHWAY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2002098824-A2 | IMPROVEMENTS IN ENZYME STABILITY | UNISEARCH LIMITED (AU) | 2002-12-12 | — | — | WO | claimed |
| EP-0397652-B1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORP (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | claimed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | claimed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | claimed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2024153106-A1 | OXADIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国药科大学 | 2024-07-25 | — | — | WO | disclosed |
| CN-115974807-B | 2-Phenyl-5-biphenyl-1, 3, 4-oxadiazole compound, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-05-31 | — | — | CN | disclosed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | disclosed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | disclosed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | disclosed |
| EP-0192609-A2 | Acylated hexose derivatives and method for their preparation | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
| US-4568725-A | POLYMERS MODIFIED SULFONATE DERIVATIVES AND SULFONATED ARGININE DERIVATIVES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1986-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | RRM1 2842/4885NPY4R 398/4885NPY1R 347/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | RRM1 2190/4885NPY4R 45/4885NPY1R 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.